Medicine and Dentistry
Infection
100%
Cohort Analysis
68%
Mumps
38%
Measles
38%
Rubella
38%
Smallpox
30%
Hazard Ratio
25%
Smallpox Vaccine
22%
Measles Mumps Rubella Vaccine
20%
Poliomyelitis
20%
Measles Rubella Vaccine
20%
Measles Mumps Vaccine
20%
Pertussis
18%
Diphtheria
18%
Tetanus
18%
Malignant Neoplasm
11%
Live Vaccine
11%
Disease
11%
Long Term Survival
10%
Retrospective Cohort Study
10%
Inflammatory Bowel Disease
10%
Antibiotic Therapy
10%
Revaccination
10%
Atopic Dermatitis
10%
Influenza Vaccination
10%
Cohort Effect
10%
Mycobacterium Bovis BCG
10%
BCG Vaccination
10%
Oral Poliomyelitis Vaccine
10%
Human Respiratory Syncytial Virus
10%
Vaccinia
10%
Melanoma
10%
Odds Ratio
10%
Human Immunodeficiency Virus 1 Infection
10%
Haemophilus Influenzae Type B Vaccine
9%
Haemophilus Influenzae Type B
8%
Human Immunodeficiency Virus 1
8%
Intention-to-Treat Analysis
7%
Prevalence
7%
Proportional Hazards Model
6%
Ulcerative Colitis
5%
Wart Virus
5%
Crohn's Disease
5%
Rotavirus
5%
Clinical Trial
5%
Pharmacology, Toxicology and Pharmaceutical Science
Infection
87%
Cohort Study
65%
Measles
42%
Rubella
40%
Mumps
40%
Measles Rubella Vaccine
31%
Measles Mumps Vaccine
31%
Poliomyelitis
25%
Measles Mumps Rubella Vaccine
20%
Tetanus
20%
Diphtheria
20%
Pertussis
20%
Malignant Neoplasm
20%
Mycobacterium Bovis BCG
14%
Haemophilus Influenzae Type B
13%
Live Vaccine
12%
Antibiotics
10%
Smallpox
10%
Asthma
10%
Oral Poliomyelitis Vaccine
10%
Atopic Dermatitis
10%
Human Immunodeficiency Virus 1 Infection
10%
Human Respiratory Syncytial Virus
10%
Human Immunodeficiency Virus 1
10%
Smallpox Vaccine
10%
Influenza Vaccine
10%
Immunocompromised Patient
10%
Prevalence
9%
Measles Vaccine
7%
Chemotherapy
6%
Penicillin Derivative
6%
Solid Malignant Neoplasm
5%
Haemophilus Influenzae Type B Vaccine
5%
